Cargando…

Multiple drugs: Off-label use in coronavirus disease 2019 and increase in the viral replication of SARS-CoV-2: 5 case reports

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2021
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7787654/ http://dx.doi.org/10.1007/s40278-021-88368-6

Ejemplares similares

Multiple drugs: SARS-CoV-2 pneumonia and off-label use
Publicado: (2021)

Multiple drugs: Coronavirus disease-2019, lack of efficacy and off-label treatment: 21 case reports
Publicado: (2021)

Multiple drugs: Persistent SARS-CoV-2 viral load, prolonged or complicated COVID-19 pneumonia and off label use: case report
Publicado: (2022)

Multiple drugs: Acute pancreatitis, hypertriglyceridaemia and off-label use in coronavirus disease 2019: 2 case reports
Publicado: (2020)

Differences in Interactions Within Viral Replication Complexes of SARS-CoV-2 (COVID-19) and SARS-CoV Coronaviruses Control RNA Replication Ability
por: Faisal, H. M. Nasrullah, et al.
Publicado: (2021)

Multiple drugs: Reactivation of SARS-CoV-2 infection, vaccine failure and off label use: case report
Publicado: (2021)

On-target versus off-target effects of drugs inhibiting the replication of SARS-CoV-2
por: Sauvat, Allan, et al.
Publicado: (2020)

Multiple drugs: Off-label use and prolonged viral clearance: case report
Publicado: (2021)

The effect of whey protein on viral infection and replication of SARS-CoV-2 and pangolin coronavirus in vitro
por: Fan, Huahao, et al.
Publicado: (2020)

Tocilizumab: Viral myocarditis, increased viral replication and worsening of COVID-19 following off-label use: 2 case reports
Publicado: (2020)

Coronavirus biology and replication: implications for SARS-CoV-2
por: V’kovski, Philip, et al.
Publicado: (2020)

Multiple drugs: Prolonged viral shedding time and off-label use: case report
Publicado: (2020)

Multiple drugs: Increased blood sugar and off-label use: case report
Publicado: (2021)

Structural, glycosylation and antigenic variation between 2019 novel coronavirus (2019-nCoV) and SARS coronavirus (SARS-CoV)
por: Kumar, Swatantra, et al.
Publicado: (2020)

Chloroquine for the 2019 novel coronavirus SARS-CoV-2
por: Colson, Philippe, et al.
Publicado: (2020)

Methylprednisolone/prednisone: Accelerated viral replication following an off-label treatment: case report
Publicado: (2020)

SARS-CoV-2 viral load and replication in postmortem examinations
por: Grassi, Simone, et al.
Publicado: (2022)

Feline coronavirus drug inhibits the main protease of SARS-CoV-2 and blocks virus replication
por: Vuong, Wayne, et al.
Publicado: (2020)

Structures and functions of coronavirus replication–transcription complexes and their relevance for SARS-CoV-2 drug design
por: Malone, Brandon, et al.
Publicado: (2021)

Quinacrine, an Antimalarial Drug with Strong Activity Inhibiting SARS-CoV-2 Viral Replication In Vitro
por: Salas Rojas, Mónica, et al.
Publicado: (2021)

Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2
por: Zhou, Yadi, et al.
Publicado: (2020)

Multiple drugs: Increased corrected QT interval and off label use: case report
Publicado: (2021)

Focus on a 2019-novel coronavirus (SARS-CoV-2)
por: Zhang, Ling-Pu, et al.
Publicado: (2020)

Multiple drugs: Various toxicities, off-label use and no response to off-label therapy: case report
Publicado: (2021)

Membrane remodeling by SARS-CoV-2 – double-enveloped viral replication
por: Mohan, Jagan, et al.
Publicado: (2021)

SARS-CoV and emergent coronaviruses: viral determinants of interspecies transmission
por: Bolles, Meagan, et al.
Publicado: (2011)

Off-label use of tocilizumab for the treatment of SARS-CoV-2 pneumonia in Milan, Italy
por: Morena, Valentina, et al.
Publicado: (2020)

Multiple drugs interaction: Off-label use and increased plasma concentration of rivaroxaban: case report
Publicado: (2021)

Multiple drugs: Drugs ineffective and off-label use: case report
Publicado: (2022)

Assessing viral shedding of SARS-CoV-2 in tears in Moderate to Severe coronavirus disease 2019 (COVID-19) patients.
por: Pumma, P., et al.
Publicado: (2021)

Multiple drugs: Severe acute respiratory syndrome coronavirus 2 reinfection and off label use: case report
Publicado: (2021)

Multiple drugs: COVID-19 infection, prolonged viral shedding and off-label use: 2 case reports
Publicado: (2021)

Deferasirox/hydroxychloroquine: Various toxicities and off-label use in coronavirus disease 2019: case report
Publicado: (2021)

Author Correction: Feline coronavirus drug inhibits the main protease of SARS-CoV-2 and blocks virus replication
por: Vuong, Wayne, et al.
Publicado: (2020)

Multiple drugs: Various toxicities and off label use: 5 case reports
Publicado: (2021)

Replication of human coronaviruses SARS-CoV, HCoV-NL63 and HCoV-229E is inhibited by the drug FK506
por: Carbajo-Lozoya, Javier, et al.
Publicado: (2012)

Additional diagnostic testing of the 2019 novel coronavirus (SARS-CoV-2)
por: Vo, Van Giau, et al.
Publicado: (2020)

The immune vulnerability landscape of the 2019 Novel Coronavirus, SARS-CoV-2
por: Zhu, James, et al.
Publicado: (2020)

Are pangolins the intermediate host of the 2019 novel coronavirus (SARS-CoV-2)?
por: Liu, Ping, et al.
Publicado: (2020)

Mitochondria Targeted Viral Replication and Survival Strategies—Prospective on SARS-CoV-2
por: Gatti, Priya, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_56ccgomr3j4ku7u85h6c80c349